S&P 500   4,211.16 (+0.75%)
DOW   33,074.82 (+0.51%)
QQQ   350.23 (+0.64%)
AAPL   179.43 (+1.23%)
MSFT   329.83 (+0.44%)
META   268.87 (+1.57%)
GOOGL   123.19 (+0.26%)
AMZN   121.89 (+1.09%)
TSLA   204.09 (+0.08%)
NVDA   392.61 (+3.77%)
NIO   7.53 (+0.00%)
BABA   82.91 (+4.22%)
AMD   119.77 (+1.32%)
T   15.85 (+0.76%)
F   12.09 (+0.75%)
MU   68.85 (+0.95%)
CGC   0.85 (+1.60%)
GE   104.25 (+2.68%)
DIS   88.24 (+0.32%)
AMC   4.64 (+3.11%)
PFE   38.06 (+0.11%)
PYPL   62.74 (+1.21%)
NFLX   400.92 (+1.44%)
S&P 500   4,211.16 (+0.75%)
DOW   33,074.82 (+0.51%)
QQQ   350.23 (+0.64%)
AAPL   179.43 (+1.23%)
MSFT   329.83 (+0.44%)
META   268.87 (+1.57%)
GOOGL   123.19 (+0.26%)
AMZN   121.89 (+1.09%)
TSLA   204.09 (+0.08%)
NVDA   392.61 (+3.77%)
NIO   7.53 (+0.00%)
BABA   82.91 (+4.22%)
AMD   119.77 (+1.32%)
T   15.85 (+0.76%)
F   12.09 (+0.75%)
MU   68.85 (+0.95%)
CGC   0.85 (+1.60%)
GE   104.25 (+2.68%)
DIS   88.24 (+0.32%)
AMC   4.64 (+3.11%)
PFE   38.06 (+0.11%)
PYPL   62.74 (+1.21%)
NFLX   400.92 (+1.44%)
S&P 500   4,211.16 (+0.75%)
DOW   33,074.82 (+0.51%)
QQQ   350.23 (+0.64%)
AAPL   179.43 (+1.23%)
MSFT   329.83 (+0.44%)
META   268.87 (+1.57%)
GOOGL   123.19 (+0.26%)
AMZN   121.89 (+1.09%)
TSLA   204.09 (+0.08%)
NVDA   392.61 (+3.77%)
NIO   7.53 (+0.00%)
BABA   82.91 (+4.22%)
AMD   119.77 (+1.32%)
T   15.85 (+0.76%)
F   12.09 (+0.75%)
MU   68.85 (+0.95%)
CGC   0.85 (+1.60%)
GE   104.25 (+2.68%)
DIS   88.24 (+0.32%)
AMC   4.64 (+3.11%)
PFE   38.06 (+0.11%)
PYPL   62.74 (+1.21%)
NFLX   400.92 (+1.44%)
S&P 500   4,211.16 (+0.75%)
DOW   33,074.82 (+0.51%)
QQQ   350.23 (+0.64%)
AAPL   179.43 (+1.23%)
MSFT   329.83 (+0.44%)
META   268.87 (+1.57%)
GOOGL   123.19 (+0.26%)
AMZN   121.89 (+1.09%)
TSLA   204.09 (+0.08%)
NVDA   392.61 (+3.77%)
NIO   7.53 (+0.00%)
BABA   82.91 (+4.22%)
AMD   119.77 (+1.32%)
T   15.85 (+0.76%)
F   12.09 (+0.75%)
MU   68.85 (+0.95%)
CGC   0.85 (+1.60%)
GE   104.25 (+2.68%)
DIS   88.24 (+0.32%)
AMC   4.64 (+3.11%)
PFE   38.06 (+0.11%)
PYPL   62.74 (+1.21%)
NFLX   400.92 (+1.44%)
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Price Target & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$20.03
▼
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media

Opiant Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 2 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
6/1/22 to 6/1/23		1 Month Ago
5/2/22 to 5/2/23		3 Months Ago
3/3/22 to 3/3/23		1 Year Ago
6/1/21 to 6/1/22
Consensus Rating
Hold
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/A$42.00
Predicted UpsideN/AN/AN/A68.98% Upside
Get Opiant Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.


OPNT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OPNT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Opiant Pharmaceuticals Stock vs. The Competition

TypeOpiant PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.66
2.49
Consensus RatingHoldBuyHold
Predicted Upside1,273.51% Upside203.40% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/23/2022Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
11/22/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		B. Folkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOverweight ➝ Neutral
(Data available from 6/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












OPNT Price Target - Frequently Asked Questions

What is Opiant Pharmaceuticals's consensus rating?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Opiant Pharmaceuticals stock is Hold based on the current 2 hold ratings for OPNTthe . Learn more on OPNT's analyst rating history.

Do Wall Street analysts like Opiant Pharmaceuticals more than its competitors?

Analysts like Opiant Pharmaceuticals less than other Medical companies. The consensus rating for Opiant Pharmaceuticals is Hold while the average consensus rating for medical companies is Buy. Learn more on how OPNT compares to other companies.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:OPNT) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -